WG
EVFM

Winton Group’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Winton Group’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,009
Closed -$71K – 1587
2020
Q3 		$71K Buy
+2,009
New +$87.3K ﹤0.01% 1428

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TWMP
Taylor Wealth Management Partners Boston, Massachusetts $176M AUM 14.65% 1-Year Est. Return

Winton Group's EVFM Position: Q4 2020 in Review

Winton Group sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2020, closing a stake of 2,009 shares — an estimated $71K sold.

Winton Group first reported a position in EVFM in Q3 2020 and held it in 1 quarter. The position peaked at $71K in Q3 2020. 93 funds tracked by Wall St. Rank hold EVFM as of Q4 2020.

  • Winton Group reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Winton Group sold 2,009 Evofem Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $71K.
  • Winton Group first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Winton Group's Evofem Biosciences, Inc. Common Stock position peaked at $71K in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.